[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"invasive-ductal-carcinoma-of-female-breast\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:invasive-ductal-carcinoma-of-female-breast":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100648455","radiation-after-no-axillary-nodal-sampling-100648455",false,"NCT07723209","Radiation After No Axillary Nodal Sampling","RADIation After no Axillary Nodal Sampling (RADIANS)","RADIANS","Inclusion Criteria:\n\n* Individuals assigned Female at birth, age 40 and older\n* Breast conserving surgery without SLNB or ALND\n* All patients should be capable of giving informed consent,\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n* Histologically confirmed invasive ductal carcinoma\n* Individuals with pathologic tumor size \\\u003C3cm\n* Patients in whom partial breast is deemed technically not possible due to breast size will be considered screen failures and excluded from the trial.\n* Clinically and radiologically node-negative (no palpable nodes, negative axillary imaging)\n* Electrocorticography (ECOG) performance status 0-2\n\nExclusion Criteria:\n\n* Male\n* Transgender or non-binary individuals.\n* Mastectomy\n* Metastatic disease\n* History of ipsilateral or contralateral breast cancer.\n* Obstacles to obtaining informed consent or undergoing regular follow-up","FEMALE","40 Years",{"count":20,"type":21},105,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a single arm, pilot, prospective study to evaluate the safety of partial breast irradiation in women who undergo breast conserving surgery without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). Baseline demographic and clinical information will be collected. All patients will complete the Breast Cancer Treatment Outcome Scale (BCTOS-13) questionnaire and the Functional Assessment of Chronic Illness Therapy-Comprehensive Score for financial Toxicity at baseline and at 2 years. All patients are required to have an axillary ultrasound prior to radiation start if this was not obtained pre-operatively.",[27,28],"Early-stage Breast Cancer","Invasive Ductal Carcinoma of Female Breast","RECRUITING","2026-07-20",{"date":32,"type":33},"2026-07-23","ACTUAL",{"date":35,"type":33},"2026-07-09",{"date":37,"type":21},"2034-07-31",{"name":39,"class":40},"NYU Langone Health","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":5},"100438111","accelerated-partial-breast-irradiation-apbi-using-stereotactic-body-radiation-therapy-sbrt-100438111","NCT04985032","Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)","Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT): a Multicenter, Observational Clinical Trial","Inclusion Criteria:\n\n1. Women 50 years or older\n2. Low to intermediate grade DCIS or invasive ductal carcinoma\n3. Tumor size \\\u003C 2 cm invasive ductal carcinoma and \\\u003C 2.5 cm DCIS\n4. Well defined lumpectomy cavity on CT\n5. Clear surgical ink margins \\> 2mm for invasive cancer and \\> 3 mm for DCIS\n6. Node negative\n7. Unifocal lesion\n8. ER and\u002For PR positive\n9. HER-2 negative\n10. BRCA negative\n11. Lumpectomy cavity must be \\\u003C 30% of whole breast volume\n\nExclusion Criteria:\n\n1. Lobular histology\n2. Angiolymphatic invasion\n3. Multiple foci of disease\n4. Lymphovascular invasion\n5. Active lupus or sarcoid\n6. Distant metastases\n7. Non-epithelial malignancies\n8. Synchronous contralateral breast cancer\n9. Grade 2 or higher oncoplastic surgery\n10. Ipsilateral pacemaker\n11. Ipsilateral breast implant\n12. Neoadjuvant chemotherapy\n13. Prior ipsilateral breast cancer or thoracic radiation\n14. Poor breast integrity\n15. Paget's Disease of the nipple\n16. Pregnant patients\n17. Severe cardiac, pulmonary, or liver diseases",true,"50 Years","100 Years",{"count":53,"type":21},200,"5 Years","OBSERVATIONAL","This is a multi-institutional, prospective, observational registry investigating the safety and efficacy of Accelerated Partial Breast Irradiation (APBI) using a Stereotactic Body Radiation Therapy (SBRT) delivery technique that incorporates real-time image guidance, noncoplanar fields, and respiratory tracking. The study will accrue 200 patients who will be treated to a dose of 30 Gy over the course of 5 fractions. These subjects will then have a follow up time of 5 years",[58,28],"Ductal Carcinoma in Situ","2022-08-03",{"date":61,"type":33},"2022-08-05",{"date":63,"type":21},"2022-08-15",{"date":65,"type":21},"2027-06",{"name":67,"class":40},"RPCR, Inc."]